Cargando…

Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis

Suppressing tumors through anti‐angiogenesis has been established as an effective clinical treatment strategy. Bevacizumab, a monoclonal antibody, is commonly used in various indications. However, two major challenges limit the long‐term efficacy of bevacizumab: drug resistance and side effects. Bev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Nannan, Fan, Buxi, Sun, Yao, Xue, Peilin, Liu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637069/
https://www.ncbi.nlm.nih.gov/pubmed/37715566
http://dx.doi.org/10.1111/cas.15939
_version_ 1785146480860856320
author Kang, Nannan
Fan, Buxi
Sun, Yao
Xue, Peilin
Liu, Yu
author_facet Kang, Nannan
Fan, Buxi
Sun, Yao
Xue, Peilin
Liu, Yu
author_sort Kang, Nannan
collection PubMed
description Suppressing tumors through anti‐angiogenesis has been established as an effective clinical treatment strategy. Bevacizumab, a monoclonal antibody, is commonly used in various indications. However, two major challenges limit the long‐term efficacy of bevacizumab: drug resistance and side effects. Bevacizumab resistance has been extensively studied at the molecular level, but no drug candidates have been developed for clinical use to overcome this resistance. In a previous study conducted by our team, a major finding was that high expression of ESM1 in bevacizumab‐resistant tumors is associated with an unfavorable response to treatment. In particular, an increase in ESM1 expression contributes to heightened lung metastasis and microvascular density, which ultimately decreases the tumor's sensitivity to bevacizumab. In contrast, the silencing of ESM1 results in reduced angiogenesis and suppressed tumor growth in tumors resistant to bevacizumab. We put forward the hypothesis that targeting ESM1 could serve as a therapeutic strategy in overcoming bevacizumab resistance. In this study, a variety of anti‐ESM1 antibodies with high affinity to human ESM1 were successfully prepared and characterized. Our in vivo study confirmed the establishment of a bevacizumab‐resistant human colorectal cancer model and further demonstrated that the addition of anti‐ESM1 monoclonal antibodies to bevacizumab treatment significantly improved tumor response while downregulating DLL4 and MMP9. In conclusion, our study suggests that anti‐hESM1 monoclonal antibodies have the potential to alleviate or overcome bevacizumab resistance, thereby providing new strategies and drug candidates for clinical research in the treatment of bevacizumab‐resistant colorectal cancer.
format Online
Article
Text
id pubmed-10637069
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106370692023-11-15 Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis Kang, Nannan Fan, Buxi Sun, Yao Xue, Peilin Liu, Yu Cancer Sci ORIGINAL ARTICLES Suppressing tumors through anti‐angiogenesis has been established as an effective clinical treatment strategy. Bevacizumab, a monoclonal antibody, is commonly used in various indications. However, two major challenges limit the long‐term efficacy of bevacizumab: drug resistance and side effects. Bevacizumab resistance has been extensively studied at the molecular level, but no drug candidates have been developed for clinical use to overcome this resistance. In a previous study conducted by our team, a major finding was that high expression of ESM1 in bevacizumab‐resistant tumors is associated with an unfavorable response to treatment. In particular, an increase in ESM1 expression contributes to heightened lung metastasis and microvascular density, which ultimately decreases the tumor's sensitivity to bevacizumab. In contrast, the silencing of ESM1 results in reduced angiogenesis and suppressed tumor growth in tumors resistant to bevacizumab. We put forward the hypothesis that targeting ESM1 could serve as a therapeutic strategy in overcoming bevacizumab resistance. In this study, a variety of anti‐ESM1 antibodies with high affinity to human ESM1 were successfully prepared and characterized. Our in vivo study confirmed the establishment of a bevacizumab‐resistant human colorectal cancer model and further demonstrated that the addition of anti‐ESM1 monoclonal antibodies to bevacizumab treatment significantly improved tumor response while downregulating DLL4 and MMP9. In conclusion, our study suggests that anti‐hESM1 monoclonal antibodies have the potential to alleviate or overcome bevacizumab resistance, thereby providing new strategies and drug candidates for clinical research in the treatment of bevacizumab‐resistant colorectal cancer. John Wiley and Sons Inc. 2023-09-16 /pmc/articles/PMC10637069/ /pubmed/37715566 http://dx.doi.org/10.1111/cas.15939 Text en © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Kang, Nannan
Fan, Buxi
Sun, Yao
Xue, Peilin
Liu, Yu
Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
title Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
title_full Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
title_fullStr Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
title_full_unstemmed Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
title_short Novel specific anti‐ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
title_sort novel specific anti‐esm1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637069/
https://www.ncbi.nlm.nih.gov/pubmed/37715566
http://dx.doi.org/10.1111/cas.15939
work_keys_str_mv AT kangnannan novelspecificantiesm1antibodiesovercometumorbevacizumabresistancebysuppressingangiogenesisandmetastasis
AT fanbuxi novelspecificantiesm1antibodiesovercometumorbevacizumabresistancebysuppressingangiogenesisandmetastasis
AT sunyao novelspecificantiesm1antibodiesovercometumorbevacizumabresistancebysuppressingangiogenesisandmetastasis
AT xuepeilin novelspecificantiesm1antibodiesovercometumorbevacizumabresistancebysuppressingangiogenesisandmetastasis
AT liuyu novelspecificantiesm1antibodiesovercometumorbevacizumabresistancebysuppressingangiogenesisandmetastasis